Company / Current Liabilities
Anika Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$21.9M
FY2025
5-year range
$21.9M / $31.1M
FY2021-FY2025
Trend
-6.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 10 years, ranging from $9M in FY2016 to $31M in FY2023.
Based on SEC 10-K filings.
$22M in FY2025 with a 5-year CAGR of +6.1%.
Improved from $31M to $22M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -7.8%
- 5-Year CAGR
- +6.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.1%, indicating consistent growth.
- In FY2025, current liabilities decreased 6.0% year-over-year.
- Peak current liabilities was recorded in FY2023.
- Lowest current liabilities in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $21.9M | -6.0% |
| FY2024 | $23.3M | -25.0% |
| FY2023 | $31.1M | +11.3% |
| FY2022 | $27.9M | -6.3% |
| FY2021 | $29.8M | +83.0% |
| FY2020 | $16.3M | +0.0% |
| FY2019 | $16.3M | +44.2% |
| FY2018 | $11.3M | -13.6% |
| FY2017 | $13.1M | +48.6% |
| FY2016 | $8.8M | -49.1% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026